|
|
|
|
| Smart Sourcing: IRT/RTSM Technology Showcase (May 7, 2026, 10:00am ET) is a virtual expo for clinical research teams evaluating IRT/RTSM platforms. Attendees will see 15-minute live vendor presentations, side-by-side capability comparisons, and real-time Q&A. Designed for clinical operations, data, IT, and procurement professionals, the event helps teams confidently shortlist suppliers, accelerate vendor selection, and support patient safety, data integrity, and compliance in Phase I–IV studies. |
|
|
|
| U.S. Pharma Tariffs And MFN Become Law After April 2 Update | Guest Column | By Mathini Ilancheran, R&D, Beroe Inc. | Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them. |
|
|
|
|
| CNS Trials Are Difficult — Do They Have To Be? | Article | By Francesco Bibbiani and Marty Kraut, Avance Clinical | Clinical trials for central nervous system therapies face significant obstacles to approval, including subjective endpoints and complex patient selection. Consider a strategic approach for success. |
|
|
| Streamlining Clinical Trial Start-Up In Australia | White Paper | Southern Star Research | Gain a comprehensive overview of how sponsors can accelerate clinical trial start-up in Australia, leveraging the nation’s unique strengths as a global hub for clinical research. |
|
|
| Operationalizing Global Oncology Trials | Product | Worldwide Oncology | Fast-track development timelines through a seamlessly integrated approach that empowers biotechs to deliver life-changing therapies to patients worldwide, faster, smarter, and with purpose |
|
|
|
| Forget More Clinical Tech, We Need More Adoption | From The Editor | By Dan Schell, chief editor, Clinical Leader | At SCOPE Summit, Craig Lipset shared a blunt assessment of clinical trial innovation: the tools exist, regulators are engaged, and digital approaches offer clear quality advantages — yet adoption remains the industry’s biggest hurdle. From evolving FDA inspection expectations to the normalization (and lingering misconceptions) of decentralized trials, Lipset argues progress will depend less on new technology and more on scaling what already works. |
|
|
CHOOSE YOUR OWN ADVENTURE |
|
|
|
| You're receiving the Wednesday edition of the Clinical Leader newsletter, focusing on Decentralized Trials and Trial Management. To make changes to your newsletter selections, update your topic preferences. - Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
- Clinical Trial Technology (Tuesday)
- Decentralized Trials | Trial Management (Wednesday)
- Outsourcing Models | Regulatory & Compliance (Thursday)
- Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here. |
|
|
| Connect With Clinical Leader: |
|
|
|
